Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT247 vs NovoLog vs Fiasp CSII in T1DM
NCT05184868Phase 1Completed
- Sponsor
- Arecor Therapeutics
- Start
- Jan 2022
- Primary completion
- Sep 2022
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AT247 in type 1 diabetes mellitus (T1D) (3 arms), sponsored by Arecor Therapeutics. Primary endpoints: Area under Curve for serum insulin and Area under Curve for Glucose Infusion Rate. Started Jan 2022; status: completed.
02
Drugs
AT247
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT05184868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05184868.